Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 7c/Share
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Total interest and other expense, net: -2.62M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total interest and other expense, net: -2.62M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $3.51 million.
Updates:
Eisai Inc. beginning to market BELVIQ in the United States in early 2013, subject to the US Drug Enforcement Administration's final scheduling designation;
Regulatory authorities for the European Union and Switzerland providing their decisions on the Marketing Authorization Applications (MAA) for BELVIQ in the first half of 2013; and
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Updates:
Eisai Inc. beginning to market BELVIQ in the United States in early 2013, subject to the US Drug Enforcement Administration's final scheduling designation;
Regulatory authorities for the European Union and Switzerland providing their decisions on the Marketing Authorization Applications (MAA) for BELVIQ in the first half of 2013; and
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)
- Brinker Int'l (EAT) PT Raised to $285 at UBS Following 'Impressive' Q4 Outperformance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
